Compare Regeneron Pharmaceuticals Inc (REGN) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Banco Santander SA — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Banco Santander SA trades at $14.79 (market cap $218.36B). The key difference: Banco Santander SA is far larger — about 2.6× Regeneron Pharmaceuticals Inc's market cap, and Banco Santander SA pays the higher dividend (1.87%). Which is the better fit depends on your goals.
| REGN | SAN | |
|---|---|---|
Market Cap | $83.43B | $218.36B |
Sector | Health | Financials |
52-Week High | $852.03 | $15.05 |
52-Week Low | $555.51 | $9.65 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | 1.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Banco Santander (SAN) trades at $14.86, down 0.47% on the day, with a bullish technical signal from moving averages and a moderate buy consensus from analysts (64% buy ratings). The company reported record profitability in H1 2026 with a net income margin of 26.25% and recently completed the Webster acquisition to expand its U.S. presence, though cash flow trends show recent operational outflows.
SAN's outlook is supported by strong profitability and strategic expansion, but risks include volatile cash flows, high leverage with a debt-to-asset ratio of 17.8, and integration challenges from acquisitions. The stock offers value with a P/E of 14.47, but investors should weigh execution risks against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
